Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Enterprise Value (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Enterprise Value for 12 consecutive years, with -$297.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 8.28% to -$297.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$297.0 million, a 8.28% increase, with the full-year FY2025 number at -$297.0 million, up 8.28% from a year prior.
  • Enterprise Value was -$297.0 million for Q4 2025 at Iovance Biotherapeutics, up from -$300.8 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$164.2 million in Q3 2024 to a low of -$626.3 million in Q1 2023.
  • A 3-year average of -$320.8 million and a median of -$301.0 million in 2025 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 54.57% in 2024, then crashed 83.21% in 2025.
  • Iovance Biotherapeutics' Enterprise Value stood at -$279.9 million in 2023, then decreased by 15.69% to -$323.8 million in 2024, then increased by 8.28% to -$297.0 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Enterprise Value are -$297.0 million (Q4 2025), -$300.8 million (Q3 2025), and -$301.2 million (Q2 2025).